Cytokinetics (CYTK)

Mar 31, 2025, 4:00 PM EDT - 2 days ago

Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 20, 2025, 7:30 AM EDT - 13 days ago

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

Mar 18, 2025, 4:00 PM EDT - 15 days ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 17, 2025, 8:00 AM EDT - 16 days ago

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo

Mar 16, 2025, 10:22 AM EDT - 17 days ago

Cytokinetics Nears Approval: 'Buy' The New Potential Cardiology Franchise With Aficamten

Mar 3, 2025, 4:00 PM EST - 4 weeks ago

Cytokinetics to Participate in March Investor Conferences

Feb 27, 2025, 7:49 PM EST - 4 weeks ago

Cytokinetics, Incorporated (CYTK) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:00 PM EST - 4 weeks ago

Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update

Feb 18, 2025, 10:20 AM EST - 6 weeks ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK EXE KRYS MARA MP

Feb 13, 2025, 4:00 PM EST - 6 weeks ago

Cytokinetics to Announce Fourth Quarter Results on February 27, 2025

Feb 11, 2025, 7:30 AM EST - 7 weeks ago

Cytokinetics Names Robert E. Landry to Board of Directors

Feb 5, 2025, 4:00 PM EST - 2 months ago

Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 12:22 PM EST - 2 months ago

Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm

Jan 30, 2025, 7:30 AM EST - 2 months ago

Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program

Jan 22, 2025, 3:43 PM EST - 2 months ago

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Jan 21, 2025, 7:30 AM EST - 2 months ago

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

Jan 13, 2025, 7:30 AM EST - 2 months ago

Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

Jan 6, 2025, 4:00 PM EST - 3 months ago

Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 4:00 PM EST - 3 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Dec 31, 2024, 8:30 AM EST - 3 months ago

Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution

Dec 23, 2024, 7:30 AM EST - 3 months ago

Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Dec 20, 2024, 12:00 AM EST - 3 months ago

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

Dec 3, 2024, 7:30 AM EST - 4 months ago

Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction

Dec 2, 2024, 4:00 PM EST - 4 months ago

Cytokinetics to Participate in December Investor Conferences

Dec 2, 2024, 7:30 AM EST - 4 months ago

Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Nov 19, 2024, 3:26 AM EST - 4 months ago

Bayer acquires rights to Cytokinetics' heart drug in Japan

Nov 19, 2024, 2:30 AM EST - 4 months ago

Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan

Nov 16, 2024, 9:00 AM EST - 4 months ago

Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024

Nov 16, 2024, 9:00 AM EST - 4 months ago

Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024

Nov 11, 2024, 7:30 AM EST - 5 months ago

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089

Nov 6, 2024, 7:58 PM EST - 5 months ago

Cytokinetics, Incorporated (CYTK) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:00 PM EST - 5 months ago

Cytokinetics Reports Third Quarter 2024 Financial Results

Oct 23, 2024, 4:00 PM EDT - 5 months ago

Cytokinetics to Announce Third Quarter Results on November 6, 2024

Oct 16, 2024, 7:30 AM EDT - 6 months ago

Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day

Sep 30, 2024, 9:20 AM EDT - 6 months ago

Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting

Sep 27, 2024, 11:00 AM EDT - 6 months ago

Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions

Sep 24, 2024, 7:30 AM EDT - 6 months ago

Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program

Sep 19, 2024, 4:00 PM EDT - 6 months ago

Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting

Sep 9, 2024, 1:11 PM EDT - 7 months ago

Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study

Sep 9, 2024, 7:30 AM EDT - 7 months ago

Cytokinetics Announces Data From Phase 1 Study of CK-4021586

Sep 5, 2024, 4:00 PM EDT - 7 months ago

Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting

Sep 1, 2024, 4:27 AM EDT - 7 months ago

Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024

Sep 1, 2024, 3:51 AM EDT - 7 months ago

Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024

Aug 29, 2024, 4:00 PM EDT - 7 months ago

Cytokinetics to Participate in September Investor Conferences

Aug 13, 2024, 4:07 PM EDT - 8 months ago

Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities

Aug 9, 2024, 9:17 PM EDT - 8 months ago

Cytokinetics, Incorporated (CYTK) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:00 PM EDT - 8 months ago

Cytokinetics Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 7:30 AM EDT - 8 months ago

Cytokinetics Announces Call for Proposals for Corporate Giving Program

Jul 25, 2024, 4:00 PM EDT - 8 months ago

Cytokinetics to Announce Second Quarter Results on August 8, 2024

Jul 24, 2024, 8:00 AM EDT - 9 months ago

Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes